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1. Introduction 
Phaeochromocytomas (PHEOs) and paragangliomas (PGLs) are catecholamine-secreting 
tumors, that arise from chromaffin cells of the adrenal medulla and extra-adrenal sites. 
Extra-adrenal phaeochromocytomas are called paragangliomas (Landers et al., 2005). The 
Prevalence of these tumors is 1:4500 and 1:1700 and an annual incidence of 3-8 cases per 1 
million per year in the general population. PHEOs/PGLs arise from three anatomically 
parts of the neural crest derived sympathy-adrenal system: adrenal medulla, sympathetic, 
and parasympathetic paraganglia (Kantorovich et al., 2010).  Extra-adrenal parasympathetic 
paragangliomas which are located predominantly in the head and neck are approximately 
95% nonsecretory. Pheochromocytomas typically occur in about 85% of cases from adrenal 
medullary chromaffin tissue and in about 15% of cases from extra-adrenal chromaffin 
tissues (Elder et al., 2005). 
1.1 Malignant pheochromocytoma 
Malignant forms of catecholamine-secreting tumors are rare. The malignancy rate is 
variable, from 2.4-26%. There are no histological proofs of malignancy for such tumors to 
date and the only accepted criterion is the presence of metastasis. The distant metastases are 
usually of hematologic origin, mostly involving bone, liver and lung (Hasani-Ranjbar, 2009, 
2010). The prevalence of metastasis is up to 36-50% for extra adrenal abdominal 
pheochromocytoma and 10% and 5% for adrenal and familial forms respectively (Whalen et 
al., 1992; O Riordan et al., 1996). Some studies have suggested that the presence of necrosis, 
vascular invasion, extensive local invasion, and high rate of mitotic figures may indicate a 
malignant behavior in pheochromocytoma. A recent study by Thompson used clinical 
features, histologic findings, and immunophenotypic studies for identifying parameters that 
may help distinguish benign from malignant pheochromocytoma. This is an Adrenal Gland 
scale Score (PASS) which is weighted for 12 specific histologic features that are more 
frequently identified in malignant pheochromocytoma. Tumors with PASS more than 4 
were biologically more aggressive than tumors with a PASS less than 4. Some 
immunohistochemical markers such as Ki-67, P52, Bcl-2 were studied to differentiate 
malignant from benign pheochromocytoma too (Strong et al.,2008).  But practically the 
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diagnosis of malignant pheochromocytoma can only be determined by presence of 
recurrence or metastatic disease at a site where chromaffin cells do not normally exist.  
1.2 Familial pheochromocytoma 
Most pheochromocytomas represent sporadic tumors. However some patients have disease 
as part of a familial disorder (15-30%). Sporadic pheochromocytomas are usually unicentric 
and unilateral while familial pheochromocytomas are often multicentric and bilateral. 
Hereditary pheochromocytoma typically present at a younger age than sporadic forms 
(Nourmann et al 2002; Manger & Gifford, 2002). 
There are several familial disorders associated with pheochromocytoma, these syndromes 
include von Hippel-Lindau (VHL) syndrome, multiple endocrine neoplasia type 2 (MEN2), 
neurofibromatosis type 1 and SDH mutation-related tumours. The approximate frequency 
of pheochromocytoma in these disorders is 50 percent in MEN2, 10 to 20 percent in VHL 
syndrome, and 0.1 to 5.7 percent with neurofibromatosis type 1 (Hasani-Ranjbar etal., 2009, 
Walter et al., 1999b; Dluhy, 2002). All of these syndromes have autosomal dominant 
inheritance (Table 1).  
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant predisposition to 
tumors of the parathyroid glands, anterior pituitary, and pancreatic islet cells. 
pheochromocytoma is very rare in MEN1 syndrome (Brandi, 2001). 
1.2.1 Multiple Endocrine Neoplasia Type 2 (MEN 2A and MEN 2B ) 
The prevalence of MEN2 syndrome is 2.5 per 100,000 in the general population. MEN2 is 
sub classified into three syndromes: MEN2A; MEN2B; and familial medullary thyroid 
cancer (FMTC). 
Multiple endocrine neoplasia type 2 (MEN2A) is characterized by pheochromocytoma 
(usually bilateral and may be asynchronous), medullary thyroid carcinoma (MTC), and 
hyperparathyroidism due to primary parathyroid hyperplasia (Noumann et al., 1993). The 
respective frequency of these tumors in MEN2 is over 90 percent for medullary thyroid 
cancer, approximately 40 to 50 percent for pheochromocytoma, and 10 to 20 percent for 
multigland.  
MEN2A is a heritable predisposition to medullary thyroid cancer, pheochromocytoma, and 
primary parathyroid hyperplasia. MEN2B shares the inherited predisposition to medullary 
thyroid cancer and pheochromocytoma that occurs in MEN2A. But in patients with MEN2B 
other clinical disorders including mucosal neuromas, typically involving the lips and 
tongue, and intestinal ganglioneuromas have to be considered. FMTC is a variant of 
MEN2A, which is associated with medullary thyroid cancer but not the other clinical 
manifestations of MEN2 syndromes (Brandi etal., 2001; Pacak et al., 2005 ). In patients with 
MEN2B, Medullary thyroid cancer is often more aggressive and of earlier onset than in 
MEN2A; so; early diagnosis and prevention are particularly critical (Donovan et al., 1989; 
Mathew et al., 1987). 
In contrast to MEN1, early diagnosis via screening of "at-risk" family members in MEN2A 
kindreds is essential because medullary thyroid cancer is a life-threatening disease that can 
be prevented by early thyroidectomy 
DNA testing has been the best screening test for this disorder since it was recognized 
that affected patients have germ-line mutations in the RET proto-oncogene on 
chromosome 10.   
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 MEN2 VHL NF1 PGL CARNEY-triad 
Major 
Features 
MTC, 
PCC , 
Primary 
para-
thyroid 
hyper-
plasia 
PCC, PGL, Retinal 
angiomas, 
Ccerebellar 
hemangioblastoma, 
Epididymal 
cystadenoma, 
Renal and 
pancreatic cysts, 
neuroendocrine 
tumors, Renal cell 
carcinoma 
café-au-lait 
macules,neuro-
fibroma, 
Freckling, optic 
glioma. Lisch 
nodules (iris 
hamartomas), 
sphenoid 
dysplasia, 
Head and 
neck,media-
stinal, 
abdominal and 
pelvic PGL, 
PGL,Gastric   
leiomyo-
sarcoma, 
Pulmonary 
condromas 
% PCC 50% 10-20% Rare(0.1-5.7% - - 
Bilateral 50-80% 50% 16% - - 
Benign 
Almost 
Always 
95% Most cases 
SDHB is more 
malignant 
- 
Extra-adrenal 
PGL 
Rare Rare Can Occur 
Usual 
manifestation
- 
Inheritance AD AD AD 
SDHB & SDHC 
& SDH%(AD), 
SDHD(MI) 
Unknown 
Gene locus 10q11.2 3p25-26 17q11.2 
SDHB1p35-36 
SDHC 1q23 
SDHD11q23 
Unknown 
catecholamine 
phenotype 
E NE E NE Unknown 
Abbreviations: VHL= von Hippel Lindau, MEN= multiple endocrine neoplasia, NF=Neurofibromatosis, 
PGL=Paraganglioma, PCC= Pheochromocytoma; MTC: Medullary thyroid cancer, SDH=succinate 
dehydrogenase type B,C,or D, AD=Autosomal Dominant, NE, norepinephrine; E, 
epinephrine,MT=Maternal Imprinting 
Table 1. Genetic conditions associated with pheochromocytoma- Clinical, biochemical and 
genetic facts. 
Numerous activating mutations throughout the RET proto-oncogene have been 
documented in persons with MEN 2A and pheochromocytoma is associated most frequently 
with mutations in codon 634 (in exon 11). MEN 2B is associated with mutations primarily in 
codon 918 (in exon 16) of the RET proto-oncogene (Mulligan et al., 1994; Carlson et al.,1994).  
1.2.2 VHL syndrome 
Von Hippel-Lindau (VHL) disease represents an alteration on VHL protein. The major 
physiological function of the VHL protein is to promote degradation of hypoxia-inducible 
factor (HIF1) that is a major factor involved in the regulation of hypoxia-related gene 
transcription (Figure 1). 
Von Hippel-Lindau (VHL) disease is manifested by a variety of benign and malignant tumors. 
The VHL phenotype includes pheochromocytoma (frequently bilateral), paraganglioma 
(rarely), retinal angiomas, cerebellar hemangioblastoma, epididymal cystadenoma, renal 
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Fig. 1. pVHL (1LQB.PDB) is shown in cartoon representation, in the upper part of the 
picture, interacting with HIF (which residues are shown as sticks). The 564 hydroxyproline 
residue of HIF, which is believed to be important in the interactions between the two 
proteins [REF: Science 296, 1886 (2002);Jung-Hyun Min,  et al.  Structure of an HIF-1a-pVHL 
Complex: Hydroxyproline Recognition in Signaling ] is indicated with a circle, and a view of the 
same hydroxyproline residue (stick) is shown in the inset image, alongside with some of the 
pVHL residues (labelled) that are located in its proximity. Mutations happening in these 
residues could be deleterious to the interaction between pVHL and HIF, and possibly 
involved in the disease phenotype. (This image has been created using PyMOL).  
and pancreatic cysts, pancreatic neuroendocrine tumors, and renal cell carcinoma (RCC) 
(Hasani Ranjbar etal., 2009; Lonser et al.,2003; Patocs et al.,2008) . 
VHL disease is divided into types I and II, based upon the likelihood of developing 
pheochromocytoma (Zbar et al., 1996). Type II families are more likely to carry a missense 
mutation in the VHL gene and are at higher risk for developing pheochromocytoma. Type II 
disease is subdivided based upon the risk of developing of RCC. Type IIA and IIB families 
have a low and high incidence of RCC, respectively, while type IIC kindreds are 
characterized by the development of pheochromocytomas only, without RCC or 
hemangioblastoma. Patients in kindreds with type I disease have a substantially lower risk 
of developing pheochromocytomas (Gomy et al., 2010).  
Clinical classification of VHL include: A. Classic VHL disease (A1: Families meeting current 
VHL diagnostic criteria with involvement of at least three VHL tumors in two distinct 
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organs; A2: Sporadic patients with involvement of at least two distinct tumors); B. 
nonclassic VHL disease, meeting criteria (B1:Families with less than 3 tumors in 2 distinct 
organs; B2: Cases meeting current diagnostic VHL criteria with limited VHL manifestations; 
C. Non classic, not meeting criteria(VHL-associated manifestations not meeting current 
diagnostic criteria) (Ciotti et al., 2009). 
The VHL tumor suppressor gene is located on chromosome 3p25-26. More than 300 
germline VHL mutations have been identified that lead to loss of function of the VHL 
protein (Kim & Kaelin,2004; Cruz et al., 2007). Missense, nonsense and splice site mutations, 
microdeletions and microinsertions are detected in approximately two-thirds of the families. 
Exon or entire gene deletions are found in 20-30% of the VHL families. Recently, real time 
quantitative PCR (RQ-PCR) and multiplex ligation-dependent probe amplification assay 
(MLPA) strategies have been proposed for detection of VHL deletions(Ciotti et al., 2009). 
Specific VHL gene mutations appear to correlate with clinical phenotype. About 95% of 
patients with VHL truncating or null mutations have VHL1 (without pheochromocytoma). 
In patients with VHL syndrome and pheochromocytoma(VHL2) 92-98% have missense 
mutations. 
1.2.3 Neurofibromatosis type 1 
Neurofibromatosis, or NF, is the term given to two neurocutaneous genetic conditions. 
Neurofibromatosis type 1, also known as von Recklinghausen's is the most common type of 
neurofibromatosis. The incidence of approximately 1 in 2600 to 1 in 3000 individuals (Lammert 
et al.,2005). Approximately one-half of the cases are familial; the remainder are new mutations 
(North K, 1993). The hallmarks of NF1 are the multiple café-au-lait spots (CALS) and 
associated cutaneous neurofibromas. Pheochromocytoma has been clinically identified in 0.1 
to 5.7 percent of patients with NF. The NF1 gene has been mapped to chromosome 17q11.2 
and cloned (ledbetter et al 1989; Shen et al., 1996; Feldkamp et al., 1998).  
Mutations in the NF1 gene result in loss of functional protein, causing the wide spectrum of 
clinical findings including NF1-associated tumors.  
No obvious genotype-phenotype correlation between small mutations (<20 base pairs) of 
the NF1 gene and a specific phenotype have been demonstrated, with the exception of the 
c.2970-2972 delAAT (p.M990del) mutation that is associated with a very mild phenotype in 
the majority of cases (Upadhyaya, et al., 2007).  
Genetic testing for NF1 is available but is not routinely performed, as the diagnosis is made 
based upon clinical phenotype.  
1.2.4 Familial paraganglioma 
Initial suggestion of genetic clustering of paraganglioma tumors date back to 1930, but mode 
of inheritance which is to be autosomal dominant with maternal imprinting in some cases 
was found by Van Der Mey in 1989. Later, several familial clusters of 
pheochromocytoma/paraganglima were described and defined as paraganglioma 
syndrome PGL1 through PGL4. PGL1 is to be related to mutation in the SDHD gene, PGL2 
to SDH5, PGL3 to mutation in SDHC and PGL4 to SDHB.  SDH-related tumorigenesis is 
believed to associate with hypoxia-inducible factor (HIF)/angiogenesis pathway 
(Kantorovich et al., 2010; López-Jiménez et al.,2010). 
In this chapter three families with different forms of familial pheochromocytoma has been 
shown. All of the presented patients have had malignant pheochromocytoma and an 
unusual presentation.   
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2. Patients and data collection 
Three families with familial pheochromocytoma were evaluated for past medical history 
and complete physical examination in endocrine ward, Shariati hospital, Tehran University 
of Medical science. The case-notes and hospital databases were examined for additional 
required data. The tumor size was taken as the widest diameter recorded on pathological 
report or radiological, if the tumor had not been removed.  Operative reports were reviewed 
to determine intra operative findings and types of surgical procedures. If there was evidence 
of extra-adrenal disease and if additional organ resection was necessary, specific notes were 
made.  
All pheochromocyroms in this study were arising from the adrenal gland and no extra 
adrenal or paraganglioma was included.  Adrenal bed recurrence was not a criterion for 
malignancy. The metastases were documented in all malignant cases.  Metastatic disease 
was defined as evidence of distant spread in tissue not normally containing chromaffin 
tissue i.e. bone, liver, lung or lymph nodes. 
2.1 Biochemical testing and localization studies 
Routine biochemical tests, evaluation of 24 hours urine catecholamine metabolites, 
abdominal computed tomography (CT) or magnetic resonance imaging (MRI) and/or 131 
Iodine_metaiodobenzylguanidine (MIBG) were done too. The malignant 
pheochromocytoma was diagnosed based on presence or absence of metastasis in 
radiological or pathological report.  
2.2 Genetic analysis 
2.2.1 RET proto-oncogene mutation screening 
Genetic screening tests were done in family members. RET proto-oncogene mutation 
screening for exones 10, 11, 13 ,14, 15, 16 were examined by PCR and direct DNA 
sequencing. In patient 1, 4 and 5: Exons 10, 11, 13, 14, 15, and 16 RET proto-oncogene were 
examined by PCR and direct DNA sequencing (Alvandi et al., 2007). 
2.2.2 VHL gene mutation screening 
For VHL gene mutation screening, analysis of VHL gene was performed using Cruz et al 
protocol (Hasani-Ranjbar et al., 2009; Cruz et al., 2007). Exons 1, 2, 3 of VHL gene was 
amplified by PCR with the following primers:  
1F - 5’ CCATCCTCTACCGAGCGCGCG 3’;  
1R - 5’ GGGCTTCAGACCGTGCTATCG2; 
3 F - 5’ TGCCCAGCCACCGGTGTG 2; 
3 R - 5’  GTCTATCCTGTACTTACCACAACA; 
3F - 5’ CACACTGCCACATACATGCACTC 3’; 
 3R - 5’ACTCATCAGTACCATCAAAAGCTG 3’.  
Both forward and reverse strands were subjected to direct sequencing after PCR 
amplification. (Hasani-Ranjbar et al., 2009). 
2.3 Protein modeling 
The PDB file 1LM8 and 1VCB were used in the modeling work in order to find the potential 
impact of the residue mutation on the protein structure. NCBI blast module was used to 
determine the degree of residue conservation. In silico mutation was achieved with Swiss-
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PdbViewer v.4 and minimization of the structure was done with the use of NOMAD-Ref 
server (http://lorentz.immstr.pasteur.fr/gromacs) (Lindahl  et al., 2006). 
3. Results 
3.1 Family 1 
The index patient was born to non related parents of Persian origin, Presented with thyroid 
nodule at the age of 48 years. His past medical history was unremarkable. He had no history 
of hypertensive crisis or headache. His daughter has had medullary thyroid cancer. And 
total thyroidectomy was done for her at the age of 23. Fine needle aspiration biopsy in the 
father was compatible with MTC and preoperational screening for pheochromocytoma was 
in favor of bilateral adrenal mass.  
 DNA was isolated from peripheral blood leucocytes using salting out method. Exones 10, 
11, 13, 14, 15, 16 of RET proto-oncogene localized to 10q11.2 was examined by direct DNA 
sequencing. This resulted in identification of mutations in Exon 11, codon 634, TGC>CGC 
(Cystein>Arginine), which was indicative of hereditary MTC and Pheochromocytoma. The 
presence of this mutation was confirmed by sequencing of the complementary strand as 
well. This mutation was found in 2 other daughters and one of his sons and one of his 
nephews too.  
One of the daughters  (Figure 2, Patient 1) had thyroid nodule and complete evaluation was 
consistent with medulary thyroid cancer. Biochemical tests and radiological study for 
pheochromocytoma was done and the results were against adrenal mass. There was no 
evidence in favor of pheochromocytoma or Medullary thyroid cancer in three other RET 
proto-oncogen cariers. However total prophylactic thyroidectomy was done for all of them.   
 
 
Fig. 2. Genetic relationship of multiple endocrine neoplasia type 2. 
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Bilateral adrenalectomy and then total thyroidectomy was done for the index patient (Figure 
2, index patient). 2 years after bilateral adrenalectomy the patient presented with 
hypertention crisis and headache as he was on replacement therapy with prednisolon,  
Fludrocortisone and levothyroxine. Biochemical tests for pheochromocytoma and 
abdominal MRI was in favor of a 30 mm right adrenal mass. Evaluation for 
hyperparathyroidism was negative in all family members. 
3.2 Family 2 
Five sisters of Persian origin with grave clinical features of pheochromocytoma have been 
reported in our previous work (Hasani-Ranjbar et al, 2009). The index patient presented 
with cerebal hemorrhage and coma at the age of 29 years. After complete evaluation 
malignant metastatic pheochromocytoma confirmed and the patient was operated. Clinical 
manifestation of VHL, MEN syndrome and neurofibromatosis were negative in this patient 
and his family. Evaluation of other family members was consistent with malignant 
pheochromocytoma in four sisters. Bilateral adrenalectomy was done for them. 2 of these 
sisters died because of complication of pheochromocytoma.  
3.2.1 Genetic analysis 
Genetic analysis of VHL gene was in favor of this syndromic pheochromocytoma. Sequence 
analysis of VHL gene exons showed presence of a missense mutation (499C>T in exon 3).  
3.2.2 Protein modeling  
Arg 167 was found to be highly conserved among various species. Its mutation to 
tryptophan was observed to affect the hydrogen bondings of that residue within pVHL 
itself, and probably causing changes in the tertiary structure of the protein. In silico mutation 
of the residue and subsequent minimization of the Trp167 containing structure was 
performed and an overall RMSD of 0.519 A ° was obtained for the mutated structure with 
the use of backbone only, and 0.597 A ° with the use of all atoms. The most affected residue 
was found to be Leu 169 with RMSD of 1.902 (backbone) and 2.665 A °(all atoms). Figure 3 
shows the position of Arg 167 in the pVHL tertiary structure (figure 3).  
3.3 Family 3  
A 45 year old man presented with abdominal pain and hypertension from 1 year ago. The 
patient was a known case of neurofibromatosis type 1 that presented at the age of 15 year 
with hyperpigmented and hypopigmented lesions in trunk, arms, feet and axillary areas. 
Family history was positive for neurofibromatosis in his mother and brother.  
Biochemical tests and imaging was compatible with malignant pheochromocytoma. The size 
of mass was 120*70 mm. Left adrenalectomy and nephrectomy and splenectomy were done 
for him. After surgery the symptoms improved and blood pressure was controlled. The 
patient had poor compliance in follow up.  
After 5 years he was admitted again for evaluation of hypertensive crisis. Again biochemical 
tests were consistent with pheochromocytoma and relapse. Imaging study and liver biopsy 
confirmed metastatic pheochromocytoma  to liver and para-aortic area. 131I-MIBG therapy 
was done for him. 
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Fig. 3. pVHL (1LQB.PDB) is shown in cartoon representation, in the left part of the picture, 
interacting with Elongin C (right). The location of Arg 167 and Leu 169 residues is indicated 
with labels, and the residues are shown as sticks . Mutation of Arg 167 to Trp is suggested to 
affect both secondary and tertiary structure of pVHL. (This image has been 
created using PyMOL).  
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4. Discussion 
Here we present three distinct families with intra adrenal pheochromocytoma (Table 2).  
 
 
Abbreviations: VHL= von Hippel Lindau, MEN= multiple endocrine neoplasia, NF=Neurofibromatosis, 
Family 1=MEN2, Family 2= VHL, Family 3=NF, MTC=Medulary Thyroid Cancer, I131 MIBG = 131 
Iodine_metaiodobenzylguanidine 
Table 2. Genetic mutations and disease phenotype in the MEN 2, VHL and NF1 families. 
www.intechopen.com
Familial Catecholamine-Secreting Tumors  
- Three Distinct Families with Hereditary Pheochromocytoma  159 
4.1 Family 1 
The index patient in family 1 who presented with thyroid nodule diagnosed as MEN 2 
syndrome according to MTC and pheochromocytoma. The patient had no symptom or sign 
for pheochromocytoma. It is obviously known that when pheochromocytoma is associated 
with the multiple endocrine neoplasia type 2 (MEN2) syndrome, symptoms are present in 
only about one-half of patients and only one-third has hypertension (Pomares et al., 1998).  
Evaluation for primary parathyroid hyperplasia was negative in him and his family. In 
addition no mucosal neuromas on the lips and tongue were detected. The patient had 
MEN2B phenotype. As we mentioned before, MEN2B shares the inherited predisposition to 
medullary thyroid cancer and pheochromocytoma that occurs in MEN2A. There are, 
however, important clinical differences. Patients with MEN2B tend to have mucosal 
neuromas and intestinal ganglioneuromas. Many of these patients have development 
abnormalities, a Marfanoid habitus, and myelinated corneal nerves. Furthermore, the tumor 
is often more aggressive and of earlier onset than in MEN2A; as a result, early diagnosis and 
prevention for other family members was very critical (Donovan et al., 1989; Mathew et al., 
1987).  Since MEN2B is caused by specific RET mutations we conducted genetic evaluation 
for categorization of the syndrome (MEN2A versus MEN2B) (Eng et al., 1996). The clinical 
feature was matched with MEN2B which is actually more aggressive. On the other hand 
genetic evaluation was consistent with a known mutation related to MEN2A in which 
prophylactic thyroidectomy is recommend to be done in carriers later. As we showed in 
results we identified mutations in Exon 11, codon 634, TGC>CGC (Cystein>Arginine), 
which was indicative of MEN2A syndrome.  
The penetrance of hyperparathyroidism in those with mutations at this site is about 20 
percent. Even with the same mutation the penetrance of hyperparathyroidism within 
families varies from 9 to 34 percent (Schunffenecker et al., 1998).  
4.2 Family 2 
Family 2 is an unusual form of VHL syndrome with malignant intra adrenal 
pheochromocytoma and retinal angioma diagnosed as VHL type 2. Clinical manifestation of 
VHL, MEN syndrome and neurofibromatosis were negative in index patient and his family 
up to 9 years when retinal angioma was detected. All clinical manifestation and genetic and 
protein modeling methods have been described in our previous work which published in 
familial cancer journal (Hasani-Ranjbar et al., 2009). 
In this paper we reported the presence of a novel single nucleotide mutation in exon 3 of 
VHL gene c499 C>T causing substitution of Arginine by Tryptophan at position 167 (R 167 
W) (Hasani-Ranjbar et al., 2009). This family has been followed for at least 9 years as RET 
negative isolated familial pheochromocytoma, finally diagnosed as VHL disease according 
to retinal angioma and VHL gene mutation. As we noted before malignant 
pheochromocytoma is very rare in VHL disease and other familial forms of 
pheochromocytoma.  
Although clinical criteria were originally developed for the diagnosis of VHL based upon 
the finding of more than one VHL-associated tumor, now detection of a germline mutation 
in the VHL gene is typically used to establish the diagnosis, particularly in patients with a 
single manifestation of the condition (Lonser et al., 2003). 
On average about 10 to 20% of patients with VHL disease develop pheochromocytoma, but 
this incidence varies dramatically from family to family depending on the specific mutation 
(Koch et al., 2002; Karsdrop et al., 1994; Lamiell et al., 1989; Linehan et al., 1995) 
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In pheochromocytoma associated with von Hippel-Lindau disease, 35 percent of patients 
have no symptoms, a normal blood pressure, and normal laboratory values for fractionated 
catecholamines and metanephrines (Walter et al., 1999b). In our report all patients had 
aggressive disease and only one of the family members was asymptomatic diagnosed as 
adrenal pheochromocytoma based on  screening tests (Table2)(Hasani-Ranjbar et al., 2009).  
Malignant pheochromocytomas are histologically and biochemically the same as benign 
ones. The only reliable clue to the presence of a malignant pheochromocytoma is local 
invasion or distant metastases, which may occur as long as 20 years after resection 
(Goldstein et al., 1999; Pattarino & Bouloux 1996). 
A recent study showed high risk factors predictive factors of malignant pheochromocytoma 
include, large (5 cm or greater) or heavy (250 gm or greater) tumors, multifocal and extra-
adrenal tumors, early onset postoperative hypertension and higher plasma or urine 
metadrenaline (Feng et al., 2011). An initial report suggests that inhibin/activin beta-B 
subunit expression may help distinguish between benign and malignant disease; expression 
was strong or moderate in almost all benign adrenal pheochromocytomas (Salmenkivi et al., 
2001). Also, expression of the 3 angiogenesis or metastasis related genes VEGF, Cox-2 and 
MVD helps determine the diagnosis of malignancy and suggests strict followup (Gimenez-
Roqueplo et al., 2003; Brouwers et al., 2006). 
4.2.1 Protein modeling 
pVHL makes interactions with Elongin B and C, as well as HIF. The H1 helix of pVHL , 
where Arg 167 is located, is the interface between this protein and Elongin C, and a place 
where missense mutations occur frequently (Stebbinset et al., 1999). It seems that Arg 167 is  
involved in the correct positioning of the H1 helix, and that its mutation can also affect the 
hydrophobic interactions of Leu 168 with neighbour residues of Elongin C. the overall result  
is the disruption of some pVHL interactions with Elongin C (Figure 3).    
4.3 Family 3 
Family 3 is a kindred with neurofibromatosis and a member (A 45 year old man) with 
hypertension diagnosed as malignant pheochromocytoma. Hypertension is a frequent 
finding in adults with NF1 and may develop during childhood but pheochromocytoma is a 
much less common etiology. In these patients, the catecholamine-secreting tumor is usually 
a solitary benign adrenal pheochromocytoma, occasionally bilateral adrenal 
pheochromocytoma, and rarely a peri adrenal abdominal paraganglioma . Although 
neurofibromatosis type 1 as an autosomal dominant disorder is the most common familial 
cancer syndrome predisposing to pheochromocytoma, the risk of pheochromocytoma in this 
disorder is about 1% (Huson et al 1989; Riccardi et al., 1991). 
 Pheochromocytomas in patients with neurofibromatosis type 1 occur at the fifth decade. 
Our patient was a 45 years old man with an unusual presentation of pheochromocytma. 
Currently, except for the presence of the SDHB mutation, large size or an extra-adrenal 
location of the primary tumor, there are no reliable markers for predicting a high likelihood 
of developing metastatic disease.  Pheochromocytoma in neurofibromatosis is usually 
benign and unilateral. Based on genetic background our expectation before surgery was a 
benign non metastatic tumor. As we mentioned before, the patient had a metastatic tumor 
and after 5 years metastasis to liver and para-aortic lymph nodes deteriorated the clinical 
course of disease.  It seems to us that large mass (as detected in this patient firstly) beside 
local invasion  is a critical predicting factor to malignancy and may have the highest impact 
for detecting metastasis in future. 
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At first we treated the patient with surgical resection of the adrenal mass, but in follow up 
for treatment of distance metastasis the only available modality was MIBG therapy. 
Considering positive MIBG scan we predicted that the tumor could up take iodine. To date, 
beside surgery, 131I-MIBG therapy is the single most valuable therapy for malignant 
pheochromocytomas. Results of a phase II trial using high dose I131 MIBG demonstrated 
22% partial or complete response and 35% of patients having some degree of response (i.e. 
biochemical) without demonstrated progressive disease (Gonias  et al.,2009). For future our 
plan could be chemoembolization of the liver if there is persistent disease. 
5. Acknowledgment 
We thank all the VHL, MEN and NF families and patients.  
6. References 
Alvandi, E., Pedram, M., Soroush, A.R., Noori Naier, B., Akrami, S.M. (2007), Detection of 
RET Proto-oncogene Cys634Arg Mutation, the Cause of Medullary Thyroid 
Carcinoma, in an Iranian Child. Iran J Pediatr Suppl,2, 301 
Brandi, M.L., Gagel, R.F., Angeli, A., Bilezikian, J.P., Beck-Peccoz, P., Bordi, C., Conte-
Devolx, B., Falchetti, A., Gheri, R.G., Libroia, A., Lips, C.J., Lombardi, G., Mannelli, 
M., Pacini, F., Ponder, B.A., Raue, F., Skogseid, B., Tamburrano, G., Thakker, R.V., 
Thompson, N.W., Tomassetti, P., Tonelli, F., Wells, S.A. Jr., Marx, S.J., 
(2001),Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin 
Endocrinol Metab, 86,12,5658. 
Brouwers, F.M., Eisenhofer, G., Tao, J.J., Kant, J.A., Adams, K.T., Linehan, W.M., Pacak, 
K.,(2006), High frequency of SDHB germline mutations in patients with malignant 
catecholamine-producing paragangliomas: implications for genetic testing. J Clin 
Endocrinol Metab,91,11,4505. 
Carlson, K.M., Dou, S., Chi, D., Scavarda, N., Toshima, K., Jackson, C.E., Wells, S.A. Jr., 
Goodfellow, P.J., Donis-Keller, H., (1994),Single missense mutation in the tyrosine 
kinase catalytic domain of the RET protooncogene is associated with multiple 
endocrine neoplasia type 2B, Proc Natl Acad Sci U S A, 91,4,1579-83. 
Ciotti, P., Garuti, A., Gulli, R., Ballestrero, A., Bellone ,E., Mandich, P.,(2009), Germline 
mutations in the von Hippel-Lindau gene in Italian patients. Eur J Med 
Genet.,52,5,311-4. Epub 2009 May 21. 
Cruz, J.B., Fernandes, L.P., Clara, S.A., Conde, S.J., Perone, D., Kopp, P., Nogueira, C.R., 
(2007), Molecular analysis of the Von Hippel-Lindau (VHL) gene in a family with 
non-syndromic pheochromocytoma: the importance of genetic testing. Arq Bras 
Endocrinol Metabol , 51,1463-1467. 
Donovan, D.T., Levy, M.L., Furst, E.J., Alford, B.R., Wheeler, T., Tschen, J.A., Gagel, R.F, 
(1989),Familial cutaneous lichen amyloidosis in association with multiple endocrine 
neoplasia type 2A: a new variant. Henry Ford Hosp Med J,37,3-4,147. 
Dluhy, R.G.,(2002), Pheochromocytoma--death of an axiom. N Engl J Med, 346,19,1486. 
Elder, E.E., G. Elder, and C. Larsson, (2005),Pheochromocytoma and functional 
paraganglioma syndrome: no longer the 10% tumor. J Surg Oncol, 89,3, 193-201. 
Eng, C., Clayton, D., Schuffenecker, I., Lenoir, G., Cote, G., Gagel, R.F., van Amstel, H.K., 
Lips, C.J., Nishisho, I., Takai, S.I., Marsh, D.J., Robinson, B.G., Frank-Raue, K., 
Raue, F., Xue, F., Noll, W.W., Romei, C., Pacini, F., Fink, M., Niederle, B., Zedenius, 
J., Nordenskjöld, M., Komminoth, P., Hendy, G.N., Mulligan, L.M.,(1996), The 
www.intechopen.com
 Pheochromocytoma – A New View of the Old Problem 162 
relationship between specific RET proto-oncogene mutations and disease 
phenotype in multiple endocrine neoplasia type 2. International RET mutation 
consortium analysis. JAMA,276,19,1575. 
Eng, C., Guillausseau, P.J., Lenoir, G.M., (1998),Risk and penetrance of primary 
hyperparathyroidism in multiple endocrine neoplasia type 2A families with 
mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs à 
Calcitonine. J Clin Endocrinol Metab,83,2,487. 
Feldkamp, M.M., Gutmann, D.H., Guha, A.,(1998), Neurofibromatosis type 1: piecing the 
puzzle together. Can J Neurol Sci, 25,3,181. 
Feng, F., Zhu, Y., Wang, X., Wu, Y., Zhou, W., Jin, X., Zhang, R., Sun, F., Kasoma, Z., Shen, 
Z. (2011),Predictive Factors for Malignant Pheochromocytoma: Analysis of 136 
Patients.J Urol, Mar 16 
Gonias, S., Goldsby, R., Matthay, K.K., Hawkins, R., Price, D., Huberty, J., Damon, L., 
Linker, C., Sznewajs, A., Shiboski, S., Fitzgerald, P.,(2009), Phase II study of high-
dose [131I]metaiodobenzylguanidine therapy for patients with metastatic 
pheochromocytoma and paraganglioma. J Clin Oncol ,1,27,25,4162-8. Epub 2009 Jul 
27 
Gimenez-Roqueplo, A.P., Favier, J., Rustin, P., Rieubland, C., Crespin, M., Nau, V., Khau, 
Van Kien, P., Corvol, P., Plouin, P.F., Jeunemaitre, X., (2003),COMETE Network 
,Mutations in the SDHB gene are associated with extra-adrenal and/or malignant 
phaeochromocytomas. Cancer Res,63,17,5615. 
Goldstein, R.E., O'Neill, J.A. Jr., Holcomb, G.W. 3rd, Morgan, W.M. 3rd, Neblett, W.W. 3rd, 
Oates, J.A., Brown, N., Nadeau, J., Smith, B., Page, D.L., Abumrad, N.N., Scott, 
H.W. Jr.,(1999), Clinical experience over 48 years with pheochromocytoma. Ann 
Surg,229,6,755-64; discussion 764-6 
Gomy, I., Molfetta, G.A., de Andrade Barreto, E., Ferreira, C.A., Zanette, D.L., Casali-da-
Rocha, J.C., Silva, W.A. Jr.(2010), Clinical and molecular characterization of 
Brazilian families with von Hippel-Lindau disease: a need for delineating 
genotype-phenotype correlation. Fam Cancer, 2010 ,9,4,635-42. 
Hasani-Ranjbar, S., Amoli, M.M., Ebrahim-Habibi, A., Haghpanah,V., Hejazi, M., Soltani, A., 
Larijani, B.,(2009), Mutation screening of VHL gene in a family with malignant 
bilateral pheochromocytoma: from isolated familial pheochromocytoma to von 
Hippel-Lindau disease. Fam Cancer,8,4,465-71. Epub 2009 Aug 1. 
Hasani-Ranjbar, S., Amoli, M.M., Ebrahim-Habibi, A., Gozashti, M.H., Khalili, N., 
Sayyahpour, F.A., Hafeziyeh, J., Soltani, A., Larijani, B.,(2010), A new frameshift 
MEN1 gene mutation associated with familial malignant insulinomas. Fam Cancer, 
Dec 24. 
Hachen, R., Barnicoat, A., Li, H., Wallace, P., Van Biervliet, J.P., Stevenson ,D., Viskochil, D., 
Baralle, D., Haan, E., Riccardi, V., Turnpenny, P., Lazaro, C., Messiaen, L., 
(2007),An absence of cutaneous neurofibromas associated with a 3-bp inframe 
deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically 
significant NF1 genotype-phenotype correlation. Am J Hum Genet, 80,1,140. 
Huson, S.M., Compston, D.A., Clark, P., Harper, P.S., (1989),A genetic study of von 
Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, 
mutation rate, and effect of parental transmission on severity, J Med Genet, 26,11, 
704-11. 
Kantorovich, V., King, K.S., Pacak, K.,(2010), SDH-related pheochromocytoma and 
paraganglioma. Best Pract Res Clin Endocrinol Metab,24,3,415-24. 
www.intechopen.com
Familial Catecholamine-Secreting Tumors  
- Three Distinct Families with Hereditary Pheochromocytoma  163 
Karsdorp, N., et al., Von Hippel-Lindau disease: new strategies in early detection and 
treatment. Am J Med, 1994. 97(2): p. 158-68. 
Koch, C.A., Huang, S.C., Zhuang, Z., Stolle, C., Azumi, N., Chrousos, G.P., Vortmeyer, A.O., 
Pacak, K., (2002),Somatic VHL gene deletion and point mutation in MEN 2A-
associated pheochromocytoma. Oncogene,  21,3, 479-82. 
Kim, W.Y., Kaelin, W.G. (2004) Role of VHL gene mutation in human cancer. J Clin Oncol, 
22, 4991-5004 . 
Lammert, M., Friedman, J.M., Kluwe, L., Mautner, V.F.,(2005),Prevalence of 
neurofibromatosis 1 in German children at elementary school enrollment. Arch 
Dermatol,141,1,71. 
Lamiell, J.M.,  Salazar F.G., &  Hsia Y.E. (1989), von Hippel-Lindau disease affecting 43 
members of a single kindred. Medicine (Baltimore), 68,1, 1-29. 
Linehan, W., Lerman, M. &  Zbar,B., (1995),Identification of the VHL Gene: Its Role in Renal 
Carcinoma, JAMA,  273, 564-570. 
Ledbetter, D.H., Rich, D.C., O'Connell, P., Leppert, M., Carey, J.C., (1989),Precise localization 
of NF1 to 17q11.2 by balanced translocation. Am J Hum Genet, 44,1,20. 
Lenders, J.W., Eisenhofer, G., Mannelli, M., Pacak, K., (2005),Phaeochromocytoma. Lancet., 
20-26,366(9486),665-75. 
Lindahl ,E., Azuara, C., Koehl, P., Delarue, M., (2006) NOMAD-Ref: visualization, 
deformation and refinement of macromolecular structures based on all-atom 
normal mode analysis. Nucleic Acids Res, 34,W52–W56].  
Lonser, R.R., Glenn, G.M., Walther, M., Chew, E.Y., Libutti, S.K., Linehan, W.M., Oldfield, 
E.H. (2003),von Hippel-Lindau disease. Lancet,361,9374,2059. 
López-Jiménez, E., Gómez-López, G., Leandro-García, L.J., Muñoz, I., Schiavi, F., Montero-
Conde, C., de Cubas, A.A., Ramires, R., Landa, I., Leskelä, S., Maliszewska, A., 
Inglada-Pérez, L., de la Vega, L., Rodríguez-Antona , C., Letón, R., Bernal, C., de 
Campos, J.M., Diez-Tascón, C., Fraga, M.F., Boullosa, C., Pisano, D.G., Opocher, G., 
Robledo, M., Cascón, A. (2010),Research resource: Transcriptional profiling reveals 
different pseudohypoxic signatures in SDHB and VHL-related 
pheochromocytomas. Mol Endocrinol. 24,12,2382-91. Epub 2010 Oct 27. 
Mathew, C.G., Chin, K.S., Easton, D.F., Thorpe, K., Carter, C., Liou, G.I., Fong, S.L., Bridges, 
C.D., Haak, H., Kruseman, A.C.,(1987), A linked genetic marker for multiple 
endocrine neoplasia type 2A on chromosome 10. Nature, 328,6130,527. 
Manger., W.M.,& Gifford, R.W., (2002),Pheochromocytoma. J Clin Hypertens, 4,1, 62-72. 
Mulligan, L.M., Eng, C., Healey, C.S., Clayton, D., Kwok, J.B., Gardner, E., Ponder, M.A., 
Frilling, A., Jackson, C.E., Lehnert, H., (1994),Specific mutations of the RET proto-
oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet,6,1,70. 
Neumann, H.P., Bausch, B., McWhinney, S.R., Bender, B.U., Gimm, O., Franke, G., Schipper, 
J., Klisch, J., Altehoefer, C., Zerres, K., Januszewicz, A., Eng, C., Smith, W.M., 
Munk, R., Manz, T., Glaesker, S., Apel, T.W., Treier, M., Reineke, M., Walz, M.K., 
Hoang-Vu, C., Brauckhoff, M., Klein-Franke, A., Klose, P., Schmidt, H., Maier-
Woelfle, M., Peçzkowska, M., Szmigielski, C., Eng, C., Freiburg-Warsaw-Columbus 
(2002),Pheochromocytoma Study Group, Germ-line mutations in nonsyndromic 
pheochromocytoma. N Engl J Med,346,19,1459. 
Neumann, H.P., Berger, D.P., Sigmund, G., Blum, U., Schmidt, D., Parmer, R.J., Volk, B., 
Kirste, G., (1993),Pheochromocytomas, multiple endocrine neoplasia type 2, and 
von Hippel-Lindau disease. N Engl J Med,329,21,1531. 
North, K. (1993), Neurofibromatosis type 1: review of the first 200 patients in an Australian 
clinic. J Child Neurol. 8,4,395. 
www.intechopen.com
 Pheochromocytoma – A New View of the Old Problem 164 
O'Riordain, D.S., Young, W.F. Jr., Grant, C.S., Carney, J.A., van Heerden, J.A., (1996),Clinical 
spectrum and outcome of functional extraadrenal paraganglioma. World J Surg, 
20,7, 916-21. 
Pacak, K., Ilias, I., Adams, K.T., Eisenhofer, G., (2005),Biochemical diagnosis, localization 
and management of pheochromocytoma: focus on multiple endocrine neoplasia 
type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. 
J Intern Med, 2005, 257,1,60-8. 
Pattarino, F., Bouloux, P.M. (1996),The diagnosis of malignancy in phaeochromocytoma. 
Clin Endocrinol (Oxf), 44,239. 
Patocs ,A., Gergics, P., Balogh, K., Toth, M., Fazakas, F., Liko, I., Racz, K., (2008) Ser80Ile 
mutation and a concurrent Pro25Leu variant of the VHL gene in an extended 
Hungarian von Hippel-Lindau family,BMC Med Genet ,9, 29.  
Pomares, F.J., Cañas, R., Rodriguez, J.M., Hernandez, A.M., Parrilla, P., Tebar, F.J., 
(1998),Differences between sporadic and multiple endocrine neoplasia type 2A 
phaeochromocytoma. Clin Endocrinol (Oxf),  48,195. 
Riccardi, V.M., (1991),Neurofibromatosis: past, present, and future. N Engl J Med, 324,18, 1283-5. 
Salmenkivi, K., Arola, J., Voutilainen, R., Ilvesmäki, V., Haglund ,C., Kahri, A.I., Heikkilä, P., 
Liu, J., (2001),Inhibin/activin betaB-subunit expression in pheochromocytomas 
favors benign diagnosis.J Clin Endocrinol Metab,86,5,2231. 
Schuffenecker, I., Virally-Monod, M., Brohet, R., Goldgar, D., Conte-Devolx, B., Leclerc, L., 
Chabre, O., Boneu, A., Caron, J., Houdent, C., Modigliani, E., Rohmer, V., 
Schlumberger, M.,  
Shen, M.H., Harper, P.S., Upadhyaya, M.,(1996), Molecular genetics of neurofibromatosis 
type 1 (NF1). J Med Genet,33,1,2. 
Upadhyaya, M., Huson, S.M., Davies, M., Thomas, N., Chuzhanova, N., Giovannini, S., 
Evans, D.G., Howard, E., Kerr, B., Griffiths, S., Consoli, C., Side, L., Adams, D., 
Pierpont, M.,  
Strong, V.E., Kennedy, T., Al-Ahmadie, H., Tang, L., Coleman, J., Fong, Y., Brennan, M., 
Ghossein, R.A., (2008),Prognostic indicators of malignancy in adrenal 
pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene 
expression analysis. Surgery,143,6,759-68. Epub 2008 Apr 14. 
Stebbins, C.E., Kaelin, W.G., Pavlevitch, N.P., (1999) Structure of the VHL-ElonginC-ElonginB 
complex: implications for VHL tumor suppressor function. Science, 284:455–46]. 
Walther, M.M., Herring, J., Enquist, E., Keiser, H.R., Linehan, W.M., (1999a),von 
Recklinghausen's disease and pheochromocytomas. J Urol,162,5,1582. 
Walther, M.M., Reiter, R., Keiser, H.R., Choyke, P.L., Venzon, D., Hurley, K., Gnarra, J.R., 
Reynolds, J.C., Glenn, G.M., Zbar, B., Linehan, W.M.,(1999b), Clinical and genetic 
characterization of pheochromocytoma in von Hippel-Lindau families: comparison 
with sporadic pheochromocytoma gives insight into natural history of 
pheochromocytoma. J Urol,162,3 ,(Pt 1),659-64. 
Whalen, R.K., Althausen, A.F., Daniels, G.H. (1992), Extra-adrenal pheochromocytoma. J 
Urol, 147, 1-10. 
Zbar, B., Kishida, T., Chen, F., Schmidt, L., Maher, E.R., Richards, F.M., Crossey, P.A., 
Webster, A.R., Affara, N.A., Ferguson-Smith, M.A., Brauch, H., Glavac, D., 
Neumann, H.P., Tisherman, S., Mulvihill, J.J., Gross, D.J., Shuin, T., Whaley, J., 
Seizinger, B., Kley, N., Olschwang, S., Boisson, C., Richard, S., Lips, C.H., Lerman, 
M.,(1996), Germline mutations in the Von Hippel-Lindau disease (VHL) gene in 
families from North America, Europe, and Japan. Hum Mutat,8,4,348. 
www.intechopen.com
Pheochromocytoma - A New View of the Old Problem
Edited by Dr. Jose Fernando Martin
ISBN 978-953-307-822-9
Hard cover, 164 pages
Publisher InTech
Published online 16, December, 2011
Published in print edition December, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The book is divided into six sections. The first three sections focus on the pathophysiology of the disease,
showing anatomo- and histopathological aspects, experimental models and signaling pathways and
programmed cell death related to pheochromocytoma. The fourth discusses some specific aspects of clinical
presentation, with emphasis on clinical manifestations of headache and heart. The fifth section focuses on
clinical diagnosis, laboratory and imaging, including differential diagnosis. Finally, the last section discusses the
treatment of pheochromocytoma showing clinical cases, a case about undiagnosed pheochromocytoma
complicated with multiple organ failure and other cases about catecholamine-secreting hereditary tumors.
Thus, this book shows the disease "pheochromocytoma" in a different perspective from the traditional
approach. Enjoy your reading.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Shirin Hasani-Ranjbar, Azadeh Ebrahim-Habibi and Bagher Larijani (2011). Familial Catecholamine-Secreting
Tumors - Three Distinct Families with Hereditary Pheochromocytoma, Pheochromocytoma - A New View of the
Old Problem, Dr. Jose Fernando Martin (Ed.), ISBN: 978-953-307-822-9, InTech, Available from:
http://www.intechopen.com/books/pheochromocytoma-a-new-view-of-the-old-problem/familial-catecholamine-
secreting-tumors-three-distinct-families-with-hereditary-pheochromocytoma
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
